Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia

Scott T. Miller, Kathy Rey, Jin He, Jonathan Flanagan, Billie J. Fish, Zora R. Rogers, Winfred C. Wang, Russell E. Ware

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


The Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) confirmed safety and efficacy of hydroxyurea therapy for infants with sickle cell anemia. Treatment was associated with reduction in rates of pain, acute chest syndrome, hospitalizations, and blood transfusions; improved hematologic values; and, perhaps, preservation of organ function. During the study, a 2-year-old ingested at one time an entire 35-day supply of hydroxyurea (612mg/kg body weight). Despite a serum level of 7,756μM 4hours post-ingestion, the only toxicity was transient mild myelosuppression. With wider usage of hydroxyurea anticipated, conservative management of future overdoses seems reasonable ( NCT00006400).

Original languageEnglish (US)
Pages (from-to)170-172
Number of pages3
JournalPediatric Blood and Cancer
Issue number1
StatePublished - Jul 15 2012


  • Drug toxicity
  • Hydroxycarbamide
  • Infant
  • Poisoning

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia'. Together they form a unique fingerprint.

Cite this